 Home > Medical News > Latest Medical News > Kras/PD-1 combined first-line lung cancer debut

Kras/PD-1 combined first-line lung cancer debut

 Last Update: 2021-12-09
 Source: Internet
 Author: User

Tags

maalox drug

effexor drug interactions

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

news

Today Mirati announced some data from its Kras inhibitor adagrasib and Merck’s K drug combination in a 1b clinical trial called KRYSTAL-1

Drug source analysis

Kras is one of the most common tumor mutation genes, and G12C is a major mutation

PD-1 antibody is the safest class of tumor drugs, so it has become the mainstay of tumor combination therapy

Today, the early data of the combination of adagrasib and Yaowang cannot be said to be bad, but it is not very amazing, and it is basically in line with the predictions of experts

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.